Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD)

References

• GOLD. 2020. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 Report. cited 2020 Apr 22. Available from https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
   Google Scholar
• Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: myths, Realities and Perspectives. Drugs. 2015 Sep;75(14):1575–1585.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276.
   PubMedGoogle Scholar
• Furlow B. Moving beyond “me-too” respiratory drugs. Lancet Respir Med. 2014 Apr;2(4):261.
   PubMed Web of Science ®Google Scholar
• Gross N. The COPD Pipeline XXXVI. Chronic Obstr Pulm Dis. 2017 Oct 6;4(4):320–324.
   PubMed Web of Science ®Google Scholar
• Ward DJ, Slade A, Genus T, et al. How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001–2012. BMJ Open. 2014;4(10):e006235.
   PubMed Web of Science ®Google Scholar
• Hollis A Me-too drugs: is there a problem? WHO: intellectual Property & Public Health. 2004 cited 2020 Apr 22. Available from http://www.who.int/intellectualproperty/topics/ip/Me-tooDrugs_Hollis1.pdf
   Google Scholar
• Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther. 2010 Jul 21;4:147–158.
   PubMed Web of Science ®Google Scholar
• GOLD. Global sInitiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2019 Report. 2019 cited 2019 Mar 11 Available from https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.5-FINAL-04Nov2018_WMS.pdf
   Google Scholar
• Dorney Koppel GA. Letter to the Editor: A Patient Perspective. Chronic Obstr Pulm Dis. 2019 Nov;6(5):433–435.
   PubMedGoogle Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4:1.
   PubMed Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007 Jun;15(7):16.
   Google Scholar
• Gross N. The COPD Pipeline, XXV. Chron Obstructive Pulm Dis. 2014;1(2):250.
   PubMedGoogle Scholar
• Gross N. The COPD Pipeline XXVII. Chronic Obstr Pulm Dis. 2015;2(2):191.
   PubMed Web of Science ®Google Scholar
• Gross N. The COPD Pipeline XXX. Chron Obstructive Pulm Dis. 2016;3(1):498.
   Web of Science ®Google Scholar
• Gross N. The COPD Pipeline XXXIII. Chronic Obstr Pulm Dis. 2017;4(1):65.
   PubMed Web of Science ®Google Scholar
• Gross N. The COPD Pipeline XXXIX. Chronic Obstr Pulm Dis. 2018;5(4):338.
   PubMed Web of Science ®Google Scholar
• Gross N. The COPD Pipeline XXXX. Chronic Obstr Pulm Dis. 2019;6(1):115.
   PubMed Web of Science ®Google Scholar
• Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Bio Int. 2004;11(7):36–42.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996 Feb;17(1):1–12.
   PubMedGoogle Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacol Rev. 2020 Jan;72(1):218–252.
   PubMed Web of Science ®Google Scholar
• NCT02573155. Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects. 2015. cited 2019 Sep 25.
   Google Scholar
• NCT02814656. Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects. 2016 cited 2019 Sep 25
   Google Scholar
• NCT02570165. Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD). 2015 cited 2019 Sep 25.
   Google Scholar
• Rogliani P, Matera MG, Facciolo F, et al. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol. 2020 Mar;177(5):1150–1163.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. Chest. 2019 Apr;155(4):758–770.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(Dec):6.
   Web of Science ®Google Scholar
• NCT02573870. Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease. 2015 cited 2019 Sep 25.
   Google Scholar
• Rogliani P, Calzetta L, Cazzola M. Is ICS–LAMA an alternative option to treat patients with COPD? Lancet Respir Med. 2018;6(5):316–317.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1–9.
   PubMed Web of Science ®Google Scholar
• Lee L, Kerwin E, Collison K, et al. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study. Respir Med. 2017 Oct;131:148–157.
   PubMed Web of Science ®Google Scholar
• NCT02164539. Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component. 2014 cited 2019 Sep 25.
   Google Scholar
• Fukushima Y, Nakatani Y, Ide Y, et al. Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1187–1194.
   PubMed Web of Science ®Google Scholar
• NCT03256552. Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD. 2017 cited 2019 Sep 25.
   Google Scholar
• Leaker BR, Singh D, Nicholson GC, et al. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. Respir Res. 2019 Jun 28;20(1):132.
   PubMedGoogle Scholar
• NCT02512302. Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7). 2015 cited 2019 Sep 25.
   Google Scholar
• Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013 Sep;346(3):414–423.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Page CP, et al. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15–23.
   PubMed Web of Science ®Google Scholar
• Singh D, Abbott-Banner K, Bengtsson T, et al. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018 Nov;52:5.
   Web of Science ®Google Scholar
• NCT02542254. The Effects of RPL554 on Top of Standard COPD Reliever Medications. 2015. cited 2019 Sep 25.
   Google Scholar
• NCT03028142. The Effects of RPL554 in Addition to Tiotropium in COPD Patients. 2017 cited 2019 Sep 25.
   Google Scholar
• NCT03673670. Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD. 2018 cited 2020 Apr 27.
   Google Scholar
• NCT03443414. Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients. 2018 [cited 2020 Apr 27.
   Google Scholar
• Singh D, Martinez FJ, Watz H, et al. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020 Feb 10;21(1):47.
   PubMed Web of Science ®Google Scholar
• NCT00874497. Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema (EMPHASIS). 2009 cited 2020 Apr 23.
   Google Scholar
• Watz H, Mistry SJ, Lazaar AL, et al. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther. 2013 Oct;26(5):588–595.
   PubMed Web of Science ®Google Scholar
• NCT00549679. Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients. 2007 cited 2020 Apr 23.
   Google Scholar
• Lazaar AL, Miller BE, Tabberer M, et al. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. Eur Respir J. 2018;52:4.
   Web of Science ®Google Scholar
• NCT02130193. Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations. 2014 cited 2019 Sep 25.
   Google Scholar
• NCT03034967. Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD). 2017 cited 2020 Apr 27.
   Google Scholar
• NCT03170232. A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD). 2017 cited 2020 Apr 27.
   Google Scholar
• NCT03250689. Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD). 2017 cited 2020 Apr 27.
   Google Scholar
• Hemmerling M, Nilsson S, Edman K, et al. Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. J Med Chem. 2017 Oct 26;60(20):8591–8605.
   PubMed Web of Science ®Google Scholar
• Burris TP, Solt LA, Wang Y, et al. Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev. 2013;65(2):710–778.
   PubMed Web of Science ®Google Scholar
• NCT02648438. A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects. 2016 cited 2019 Sep 25.
   Google Scholar
• NCT02645253. A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men. 2016 cited 2019 Sep 25.
   Google Scholar
• Solomon GM, Fu L, Rowe SM, et al. The therapeutic potential of CFTR modulators for COPD and other airway diseases. Curr Opin Pharmacol. 2017;34:132–139.
   PubMed Web of Science ®Google Scholar
• Shi J, Li H, Yuan C, et al. Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Oxid Med Cell Longev. 2018;2018:6567578.
   PubMed Web of Science ®Google Scholar
• NCT02449018. A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251. 2015 cited 2019 Sep 25.
   Google Scholar
• NCT02135432. TOPIC Trial for COPD. 2014 cited 2019 Sep 25.
   Google Scholar
• NCT02366637. An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease. 2015 cited 2019 Sep 25.
   Google Scholar
• NCT02299375. Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD). 2014 cited 2019 Sep 25.
   Google Scholar
• NCT02238483. A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy. 2014 cited 2019 Sep 25.
   Google Scholar
• Jones PW, Leidy NK, Hareendran A, et al. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016 May 23;17(1):61.
   PubMedGoogle Scholar
• Cazzola M, Page CP, Calzetta L, et al. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012 Sep;40(3):724–741.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013 Jul;12(7):543–559.
   PubMed Web of Science ®Google Scholar
• NCT02294734. An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease. 2014 cited 2019 Sep 25.
   Google Scholar
• NCT02130635. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients. 2014 cited 2019 Sep 25.
   Google Scholar
• Cahn A, Hamblin JN, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69–77.
   PubMed Web of Science ®Google Scholar
• NCT02522299. A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation. 2015 cited 2020 Apr 27.
   Google Scholar
• NCT03345407. Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD).. 2017 cited 2020 Apr 27.
   Google Scholar
• Ganesan S, Faris AN, Comstock AT, et al. Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression. Respir Res. 2010 Sep;28(11):131.
   Google Scholar
• NCT01708278. Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD) (Quercetin). 2012 cited 2019 Sep 25.
   Google Scholar
• Han MK, Barreto TA, Martinez FJ, et al. Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respir Res. 2020;7:1.
   Web of Science ®Google Scholar
• Dumont EF, Oliver AJ, Ioannou C, et al. A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study. Antimicrob Agents Chemother. 2020 Apr 21;64:5.
   Web of Science ®Google Scholar
• Janissen R, Woodman A, Lee K-M, et al. Induced copy-back RNA synthesis as a novel therapeutic mechanism against RNA viruses. bioRxiv. 2020.DOI: 10.1101/2020.02.12.946558
   Google Scholar
• NCT03235726. Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug. 2017 cited 2020 Apr 23.
   Google Scholar
• Qiu S, Zhong X. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2017 Mar;11(3):147–155.
   PubMed Web of Science ®Google Scholar
• NCT02628769. A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease. 2015 cited 2020 Apr 27.
   Google Scholar
• Van Norman GA. Drugs and Devices: comparison of European and U.S. Approval Processes. JACC Basic Transl Sci. 2016 Aug;1(5):399–412.
   PubMedGoogle Scholar
• European Medicines Agency. Guideline for good clinical practice E6(R2). 2016 cited 2020 Apr 24. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf
   Google Scholar
• De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004 Sep 16;351(12):1250–1251.
   PubMed Web of Science ®Google Scholar
• Tse T, Fain KM, Zarin DA. How to avoid common problems when using ClinicalTrials. gov in research: 10 issues to consider. Bmj. 2018;361:k1452.
   PubMedGoogle Scholar
• Hartung DM, Zarin DA, Guise J-M, et al. Reporting discrepancies between the ClinicalTrials. gov results database and peer-reviewed publications. Ann Intern Med. 2014;160(7):477–483.
   PubMed Web of Science ®Google Scholar
• Andrews JA, Miller TM, Vijayakumar V, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018 May;57(5):729–734.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M, et al. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: from Isolated Airways to Patients. Adv Ther. 2019 Dec;36(12):3291–3298.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018 4;Apr(40):95–103.
   Google Scholar